title: Sirolimus-eluting stents for treatment of in-stent restenosis: immediate and late results.
abstract: We analyzed the clinical, angiographic, and late intravascular ultrasonographic findings from 140 patients whose in-stent restenosis was treated with sirolimus-eluting stents. In-stent restenosis remains the main limitation to percutaneous coronary revascularization and has a high recurrence rate after bare stent implantation. From May 2002 through July 2003, we studied 140 patients with clinical restenosis after bare-stent treatment. In 107 patients, in-stent restenosis occurred de novo; in 28 patients, this was the 2nd restenosis; and in another 5, it was the 3rd occurrence. A sirolimus-eluting stent was implanted directly after angiographic evaluation of the in-stent restenosis in 79 patients and after pre-dilation in 61 patients. All patients were given the following antithrombotic regimen: low-molecular-weight heparin, ticlopidine, and aspirin for 1 month, followed by clopidogrel and aspirin for 1 year. Primary success was achieved in 137 patients. Three patients had a non-Q wave myocardial infarction. At the 1-month evaluation, 2 patients had died: 1 due to subacute stent thrombosis and another due to acute mesenteric ischemia. After a mean follow-up of 16 +/- 4 months, the major adverse cardiac events were acute myocardial infarction due to late stent thrombosis in 2 patients and the need for target lesion revascularization in 15 patients. Late angiographic evaluation was performed in 97 patients (69%), 16 of whom had new restenosis: 14 of the restenoses were intrastent, and 2 were at the edges of the stent. Our results suggest that sirolimus-eluting stents are effective in the prevention of in-stent restenosis and, therefore, may become the leading treatment alternative for patients with in-stent restenosis.
authors.affiliation: Department of Cardiology, University Hospital Dr. Negrin, Las Palmas, Spain. grupo_corpal@arrakis.es
authors.forename: Alfonso
authors.initials: A
authors.lastname: Medina
authors.forename: Jose
authors.initials: J
authors.lastname: Suarez de Lezo
authors.forename: Manuel
authors.initials: M
authors.lastname: Pan
authors.forename: Antonio
authors.initials: A
authors.lastname: Delgado
authors.forename: José
authors.initials: J
authors.lastname: Segura
authors.forename: Djordje
authors.initials: D
authors.lastname: Pavlovic
authors.forename: Francisco
authors.initials: F
authors.lastname: Melián
authors.forename: Miguel
authors.initials: M
authors.lastname: Romero
authors.forename: Federico
authors.initials: F
authors.lastname: Segura
authors.forename: Enrique
authors.initials: E
authors.lastname: Hernández
authors.forename: Isabel
authors.initials: I
authors.lastname: Ureña
authors.forename: Juan
authors.initials: J
authors.lastname: Herrador
mesh_terms: D000368:Aged; D023903:Coronary Restenosis / Q000188:drug therapy*; D016503:Drug Delivery Systems; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D008297:Male; D011446:Prospective Studies; D020123:Sirolimus / Q000008:administration & dosage*; D015607:Stents; D013997:Time Factors
chemical_list: D007166:Immunosuppressive Agents; D020123:Sirolimus